Complex Mitochondrial Dysfunction Induced by TPP+-Gentisic Acid and Mitochondrial Translation Inhibition by

Sebastián Fuentes-Retamal1, Cristian Sandoval-Acuña2, Liliana Peredo-Silva3

  • 1Clinical and Molecular Pharmacology Program, Institute of Biomedical Sciences (ICBM), Faculty of Medicine, University of Chile, Santiago 8380453, Chile.

Cells
|February 15, 2020
PubMed

Insights

A novel compound, GA-TPP+C10, targets breast cancer cell mitochondria, inhibiting energy production and inducing cell death. Combining this with doxycycline enhances its therapeutic potential by blocking cancer cell adaptation.

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Cancer Therapeutics

Background:

  • Mitochondria are crucial in cancer development and chemoresistance, making them a key therapeutic target.
  • The compound GA-TPP+C10 selectively targets breast cancer cell mitochondria, but its mechanism was unclear.

Purpose of the Study:

  • To elucidate the mechanism of action of GA-TPP+C10 in breast cancer cells.
  • To investigate the potential of a combined therapeutic strategy involving GA-TPP+C10 and doxycycline.

Main Methods:

  • Assessing mitochondrial bioenergetics, including oxidative phosphorylation and respiration.
  • Analyzing cell cycle progression, cell death, and metabolic remodeling.
  • Investigating the effects of GA-TPP+C10 combined with doxycycline on mitochondrial function and cell viability.

Main Results:

  • GA-TPP+C10 inhibits mitochondrial respiration complexes and α-ketoglutarate dehydrogenase complex activity, leading to G1 cell cycle arrest and cell death.
  • Cancer cells exhibited metabolic adaptation, including increased glycolysis and AMPK activation, as a survival response.
  • Combined treatment with GA-TPP+C10 and doxycycline synergistically enhanced cytotoxicity by inhibiting mitochondrial translation and adaptive responses.

Conclusions:

  • GA-TPP+C10 effectively disrupts mitochondrial bioenergetics in breast cancer cells.
  • Blocking cancer cell adaptive responses to mitochondrial inhibition enhances therapeutic efficacy.
  • The combined strategy shows promise for breast cancer treatment.